Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $70.1M; returns 1 day -2.2%, 1 week +0.7%, 1 year -58.9%.

Cardiff Oncology, Inc. (CRDF) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer. Their primary focus is onvansertib, a Polo-like kinase 1 (PLK1) inhibitor, being developed for first-line treatment in RAS-mutated metastatic colorectal cancer (mCRC).

Groups CRDF belongs to

• Biotechnology
• Oncology
• Clinical Stage Biotech
• Healthcare
• Clinical Stage
• Biopharmaceutical
• Pharmaceuticals
• Cancer Therapeutics

CRDF financial model: income statement, cash flow and balance sheet